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For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor Immunology
and Biological Cancer Therapy. Under the editorial leadership of Dr. Pedro Romero and with the direct support of
the Society for Immunotherapy of Cancer (SITC), this section enriched the communication between basic
immunological sciences and the clinical investigation arena in oncology. We are re-launching this Section of JTM,
now entitled Immunobiology and Immunotherapy, succeeding Tumor Immunology and Biological Cancer Therapy.
While aiming to build on the editorial success and focus of its predecessor, this novel Section will have a broader
scope, hosting translational immunology topics pertaining to immunotherapy beyond oncology, including
disciplines such as inflammation, autoimmunity, transplantation, metabolic disorders and others. As the vision of
this re-launched Section of JTM broadens up to serve a communication need for translational immunologists
involved with immunotherapy irrespectively of the therapeutic area, a novel and focused journal entitled Journal for
Immunotherapy of Cancer (JITC) has just been initiated, sponsored by the SITC.During the last four years the JTM’s Section of Tumor
Immunology and Biological Cancer Therapy, under the
editorial leadership of Dr. Pedro Romero and with the
direct support of the Society for Immunotherapy of
Cancer (SITC) [1], has hosted nearly 70 articles – editor-
ials, reviews, research articles and others – in accordance
to its mission to enrich the communication between basic
immunological scientists and the clinical investigators in
oncology. The vision and objectives of this section co-
sponsored by the Society for Immunotherapy of Cancer
SITC (formerly the International Society for Biological
Therapy of Cancer or iSBTc), together with BioMed
Central, were articulated in an Editorial by Romero,
Fox and collaborators [2]. With that step, JTM be-
came a venue for publication of original research arti-
cles, literature reviews, opinion/position papers and a
forum to discuss the hot issues in tumor immunology
highly relevant to translating novel immune interventions.* Correspondence: abot@kitepharma.com
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reproduction in any medium, provided the orThis Section came at a turning point in cancer immuno-
therapy, when considerable advances in understanding the
relationship between the immune system and cancer
started to translate to pioneering active immunotherapies
such as the dendritic cell vaccine ProvengeW and the
checkpoint blocking antibody IpilimumabW now approved
for clinical use [3,4]. But this was just the start as this sci-
entific progress in oncoimmunology fueled unprecedented
interest and activity in designing and translating novel
immunotherapies, standalone or in context of rationally
selected combinatorial approaches. Paralleling these excit-
ing developments in oncoimmunology, a novel journal on
its own right, sponsored by SITC, is taking on the mission
to provide a venue for the ever growing scientific publica-
tion and communication need in this very field. Journal
for Immunotherapy of Cancer (JITC) [5] an open access,
peer reviewed journal, will accept various types of submis-
sions in basic tumor immunology, clinical and transla-
tional cancer immunotherapy, and immune biomarkers
with prognostic or predictive value. In addition, the new
journal will host comments and discussion on timely
topics and innovative concepts. JITC thus aims to
create a dynamic and global platform for interaction. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and implementation of cancer immunotherapy.
We are now also re-launching this section of JTM, to
be entitled Immunobiology and Immunotherapy, suc-
ceeding the Tumor Immunology and Biological Cancer
Therapy section. Through this step, the mission of JTM
will expand with this redesigned section with a much
broader scope but outside the purview of the SITC. This
renewed section will host translational immunology
topics pertaining to immunotherapy beyond oncology,
including disciplines such as inflammation, autoimmun-
ity, transplantation, metabolic disorders and others. As
immunology has evolved to be a central discipline con-
nected to a wide range of therapeutic areas, the number
and diversity of platform technologies also increased,
spanning small molecules, biologics, microbial vectors
and cells. As the vision of this novel section of JTM
broadens up to serve a communication need for transla-
tional immunologists involved with immunotherapy irre-
spectively of the therapeutic area, a cross fertilization
between various fields such as autoimmunity, infection
and cancer, could dramatically catalyze the process of
discovery and translation of innovative immunother-
apies. To illustrate that principle, it suffices to refer to
the definition of the “immunological constant of tissue
rejection” [6], a gene signature that connects immune
mediated processes across the board and that could
serve as a rich source of druggable targets and compan-
ion biomarkers for novel immune interventions designed
to either amplify or quench immune reactions in widely
different therapeutic areas. This expansion in the scope
of JTM effected by the introduction of this new section
of Immunobiology and Immunotherapy mirrors a recent
addition to the journal, namely the section of Patient-
Targeted Molecular Therapies [7], that provides a venue
for targeted therapies and translational effectiveness
pertaining to diverse therapeutic areas including in-
flammation, degenerative disorders, cancer, infection, me-
tabolism, neurologic, cardiovascular and genetic diseases,
irrespectively of the therapeutic strategy.
The Section of Immunobiology and Immunotherapy
will host a broad range of submissions in accordance
with JTM’s mission [8]: research articles, commentaries,
meeting reports, methodologies, protocols and reviews.
On behalf of the JTM we are launching the invitation
to submit your work and provide your suggestions for
the Section of Immunobiology and Immunotherapy. We
firmly believe that our journal’s commitment to provide
rapid publication, open-access and online communica-
tion at global level is key to our vision to become and
remain the premier translational medicine journal
worldwide. At last but not least, we are very thankful to
the Editorial team of the previous Section of Tumor
Immunology and Biological Cancer Therapy and we invitethem to continue to support JTM as we are expanding the
team with experts across diverse therapeutic areas.
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